Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

Fineline Cube Apr 12, 2026
Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Fineline Cube Apr 12, 2026
Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Fineline Cube Apr 12, 2026
Company Drug

Bristol-Myers Squibb’s Breyanzi Hits Primary Endpoint in Lymphoma Study

Fineline Cube Feb 11, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported positive results from the Phase II TRANSCEND FL study...

Company Drug

CSPC Pharmaceutical’s SYH2039 Wins FDA Clinical Approval for Advanced Tumors

Fineline Cube Feb 11, 2025

China’s CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration...

Company Drug

Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study

Fineline Cube Feb 11, 2025

German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...

Company Drug

CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma

Fineline Cube Feb 11, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...

Company Drug

Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025

Fineline Cube Feb 11, 2025

China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...

Company Drug

Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China

Fineline Cube Feb 11, 2025

Jiangsu-based CDMO Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has received marketing approval from China’s National...

Company Deals

R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech

Fineline Cube Feb 11, 2025

Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...

Company Deals

Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market

Fineline Cube Feb 10, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement...

Company Drug

Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials

Fineline Cube Feb 10, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...

Company Drug

CARsgen’s Allogeneic BCMA CAR-T Therapy Achieves sCR in First Patient

Fineline Cube Feb 10, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the first patient treated with its...

Company

Haisco Pharmaceutical Group Registers Delaware Subsidiary to Expand Global Operations

Fineline Cube Feb 10, 2025

Shenzhen-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the registration of a new...

Company Drug

Beijing Luzhu Submits BLA for LZ901 Herpes Zoster Vaccine to NMPA

Fineline Cube Feb 10, 2025

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a human vaccine and therapeutic biologics manufacturer, announced...

Company Drug Hospital

Hainan Boao Lecheng Pilot Zone Implements Baclofen Intrathecal Therapy

Fineline Cube Feb 10, 2025

The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica,...

Company Deals

Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs

Fineline Cube Feb 10, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in...

Policy / Regulatory

NMPA’s New Guidelines for Drug Registration Review

Fineline Cube Feb 10, 2025

A Look at the New Rules for Chemical and Biological Drug Filings in China:The Center...

Policy / Regulatory

Shanghai’s Three-Year Plan to Boost Elderly Care Quality

Fineline Cube Feb 10, 2025

A Comprehensive Look at Shanghai’s Efforts to Integrate Medical Care and Elderly Care:The Shanghai Civil...

Company Drug

NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer

Fineline Cube Feb 10, 2025

The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...

Policy / Regulatory

Tianjin Municipality Boosts Biopharmaceutical Industry with New Measures

Fineline Cube Feb 10, 2025

An In – Depth Look at Tianjin’s Efforts to Accelerate Medical Innovation and Gather Resources:The...

Company Drug

Hansoh Pharma’s Uplizna Receives Priority Review for IgG4-RD Treatment

Fineline Cube Feb 10, 2025

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

NMPA Seeks Public Feedback on Export Drug Manufacturing Rules

Fineline Cube Feb 10, 2025

An In – Depth Look at the New Draft Proposal for the Administration and Management...

Posts pagination

1 … 198 199 200 … 648

Recent updates

  • Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer
  • Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer
  • Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease
  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Company Deals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.